Xi Chen1, Aya Haggiagi2, Efstathia Tzatha3, Lisa M DeAngelis3, Bianca Santomasso3. 1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: chenx2@mskcc.org. 2. Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA. 3. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
OBJECTIVE: To report the electrodiagnostic features of immune checkpoint inhibitor (ICI)-related neuropathy. METHODS: We retrospectively reviewed clinical presentations and electrodiagnostic features of 23 patients studied after receiving immune checkpoint inhibitors (ICIs). The presentations for electrodiagnostic evaluation included an acute neuropathy or neuromuscular junction disorder. We applied established electrodiagnostic criteria for polyneuropathy and acute demyelinating neuropathy. RESULTS: We identified acute demyelinating neuropathy (13 cases), axonal sensory motor neuropathy (5), pure sensory neuropathy (4) and mononeuropathy (1). 13 patients had acute demyelinating neuropathy confirmed by demonstrating demyelination in 2 or more nerves; 3 additional patients had demyelination in only one nerve. Analysis of motor nerve conduction parameters revealed demyelination involving median and ulnar nerve distal motor latencies as well as median, ulnar and peroneal nerve conduction velocities. Conduction block was found in median, ulnar and peroneal nerves. The remaining one-third patients without demyelination had acute painful axonal neuropathy. Coexisting myopathic changes (6) and neuromuscular junction dysfunction (4) were also identified. CONCLUSIONS: Our findings suggest that, while immune-mediated motor nerve demyelination is the primary underlying mechanism of ICI-related neuropathy, axonal painful neuropathy can also be an important presentation. Early recognition and effective intervention may reduce morbidity and permanent disability. SIGNIFICANCE: Electrophysiological studies might be useful in the evaluation of ICI-related neuropathy.
OBJECTIVE: To report the electrodiagnostic features of immune checkpoint inhibitor (ICI)-related neuropathy. METHODS: We retrospectively reviewed clinical presentations and electrodiagnostic features of 23 patients studied after receiving immune checkpoint inhibitors (ICIs). The presentations for electrodiagnostic evaluation included an acute neuropathy or neuromuscular junction disorder. We applied established electrodiagnostic criteria for polyneuropathy and acute demyelinating neuropathy. RESULTS: We identified acute demyelinating neuropathy (13 cases), axonal sensory motor neuropathy (5), pure sensory neuropathy (4) and mononeuropathy (1). 13 patients had acute demyelinating neuropathy confirmed by demonstrating demyelination in 2 or more nerves; 3 additional patients had demyelination in only one nerve. Analysis of motor nerve conduction parameters revealed demyelination involving median and ulnar nerve distal motor latencies as well as median, ulnar and peroneal nerve conduction velocities. Conduction block was found in median, ulnar and peroneal nerves. The remaining one-third patients without demyelination had acute painful axonal neuropathy. Coexisting myopathic changes (6) and neuromuscular junction dysfunction (4) were also identified. CONCLUSIONS: Our findings suggest that, while immune-mediated motor nerve demyelination is the primary underlying mechanism of ICI-related neuropathy, axonal painful neuropathy can also be an important presentation. Early recognition and effective intervention may reduce morbidity and permanent disability. SIGNIFICANCE: Electrophysiological studies might be useful in the evaluation of ICI-related neuropathy.
Authors: Xi Chen; Michael D Stubblefield; Christian M Custodio; Clifford A Hudis; Andrew D Seidman; Lisa M DeAngelis Journal: J Clin Neurophysiol Date: 2013-04 Impact factor: 2.177
Authors: Caroline J Voskens; Simone M Goldinger; Carmen Loquai; Caroline Robert; Katharina C Kaehler; Carola Berking; Tanja Bergmann; Clemens L Bockmeyer; Thomas Eigentler; Michael Fluck; Claus Garbe; Ralf Gutzmer; Stephan Grabbe; Axel Hauschild; Rüdiger Hein; Gheorghe Hundorfean; Armin Justich; Ullrich Keller; Christina Klein; Christine Mateus; Peter Mohr; Sylvie Paetzold; Imke Satzger; Dirk Schadendorf; Marc Schlaeppi; Gerold Schuler; Beatrice Schuler-Thurner; Uwe Trefzer; Jens Ulrich; Julia Vaubel; Roger von Moos; Patrik Weder; Tabea Wilhelm; Daniela Göppner; Reinhard Dummer; Lucie M Heinzerling Journal: PLoS One Date: 2013-01-14 Impact factor: 3.240
Authors: Ping Zhang; Donghui Lao; Haoyan Chen; Bin Zhao; Qiong Du; Qing Zhai; Xuan Ye; Bo Yu Journal: Front Immunol Date: 2022-08-22 Impact factor: 8.786
Authors: Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751
Authors: Bart K Chwalisz; James Hillis; Amanda C Guidon; Leeann B Burton; Teilo H Schaller; Anthony A Amato; Allison Betof Warner; Priscilla K Brastianos; Tracey A Cho; Stacey L Clardy; Justine V Cohen; Jorg Dietrich; Michael Dougan; Christopher T Doughty; Divyanshu Dubey; Jeffrey M Gelfand; Jeffrey T Guptill; Douglas B Johnson; Vern C Juel; Robert Kadish; Noah Kolb; Nicole R LeBoeuf; Jenny Linnoila; Andrew L Mammen; Maria Martinez-Lage; Meghan J Mooradian; Jarushka Naidoo; Tomas G Neilan; David A Reardon; Krista M Rubin; Bianca D Santomasso; Ryan J Sullivan; Nancy Wang; Karin Woodman; Leyre Zubiri; William C Louv; Kerry L Reynolds Journal: J Immunother Cancer Date: 2021-07 Impact factor: 13.751